Search results for " Large"

showing 10 items of 392 documents

B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (D…

2017

TPS7571 Background: Patients ineligible for stem cell transplantation (SCT) or who relapse after SCT, and those who fail to respond to second-line or salvage chemotherapy, represent an unmet medical need for which new therapeutic strategies are required. MOR208 is a novel Fc-enhanced, humanized, monoclonal antibody directed against CD19. Significant single-agent activity of MOR208 in patients with R-R DLBCL (Jurczak et al., J Clin Oncol 34, 2016 [suppl; abstr 7545]) and enhancement of MOR208-mediated cytotoxicity by BEN in preclinical studies, provide a strong rationale to study MOR208 + BEN in patients with R-R DLBCL. Methods: B-MIND is a randomized (1:1), two-arm, multicenter, open-label…

0301 basic medicinePHASE II/III TRIALOncologyBendamustineCancer Researchmedicine.medical_specialtybusiness.industrymedicine.diseaseSurgeryTransplantation03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyRefractory030220 oncology & carcinogenesisInternal medicinemedicineRituximabIn patientStem cellbusinessDiffuse large B-cell lymphomamedicine.drugJournal of Clinical Oncology
researchProduct

Histologic transformation to diffuse large B cell lymphoma with profuse signet-ring cell change in bone marrow and lymph node biopsies in a patient w…

2016

0301 basic medicinePathologymedicine.medical_specialtyHistologySignet ring cellbusiness.industryGeneral Medicinemedicine.diseasePathology and Forensic Medicine03 medical and health sciencesTransformation (genetics)030104 developmental biology0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesisCytologymedicineBone marrowDifferential diagnosisbusinessLymph nodeDiffuse large B-cell lymphomaHistological correlationDiagnostic Cytopathology
researchProduct

A systematic variant screening in familial cases of congenital heart defects demonstrates the usefulness of molecular genetics in this field

2016

International audience; The etiology of congenital heart defect (CHD) combines environmental and genetic factors. So far, there were studies reporting on the screening of a single gene on unselected CHD or on familial cases selected for specific CHD types. Our goal was to systematically screen a proband of familial cases of CHD on a set of genetic tests to evaluate the prevalence of disease-causing variant identification. A systematic screening of GATA4, NKX2-5, ZIC3 and Multiplex ligation-dependent probe amplification (MLPA) P311 Kit was setup on the proband of 154 families with at least two cases of non-syndromic CHD. Additionally, ELN screening was performed on families with supravalvula…

0301 basic medicineProbandMaleCardiomyopathy22q11.2Disease030204 cardiovascular system & hematologyBioinformatics0302 clinical medicinede-novoEpidemiology3 large registriesGenetics (clinical)zic3 mutationsGeneticsHigh-Throughput Nucleotide Sequencing3. Good healthPedigreeHomeobox Protein Nkx-2.5malformationsFemaleepidemiologyHeart Defects Congenitalmedicine.medical_specialtyGenetic counselingArticle03 medical and health sciences[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMolecular geneticsGeneticsmedicineHumansMultiplex ligation-dependent probe amplificationGenetic TestingHomeodomain Proteinsdiseasebusiness.industryvariabilityGenetic Variationmedicine.diseaseGATA4 Transcription Factor030104 developmental biologyMutationEtiologycardiovascular defectsbusinessMultiplex Polymerase Chain Reactioncardiomyopathy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyTranscription Factors
researchProduct

On the structural connectivity of large-scale models of brain networks at cellular level

2021

AbstractThe brain’s structural connectivity plays a fundamental role in determining how neuron networks generate, process, and transfer information within and between brain regions. The underlying mechanisms are extremely difficult to study experimentally and, in many cases, large-scale model networks are of great help. However, the implementation of these models relies on experimental findings that are often sparse and limited. Their predicting power ultimately depends on how closely a model’s connectivity represents the real system. Here we argue that the data-driven probabilistic rules, widely used to build neuronal network models, may not be appropriate to represent the dynamics of the …

0301 basic medicineProcess (engineering)Computer scienceScienceModels NeurologicalCellular levelMachine learningcomputer.software_genreArticle03 medical and health sciencesComputational biophysics0302 clinical medicineSettore MAT/05 - Analisi MatematicamedicineBiological neural networkHumansSettore MAT/07 - Fisica MatematicaOn the structural connectivity of large-scale models of brain networks at cellular levelSettore ING-INF/05 - Sistemi Di Elaborazione Delle InformazioniNeuronsMultidisciplinaryNetwork modelsSettore INF/01 - Informaticabusiness.industryQRProbabilistic logicBrain030104 developmental biologymedicine.anatomical_structureMathematical framework Neuron networks Large‑scale model Data‑driven probabilistic rules Modeling cellular-level brain networksMedicineNeuronArtificial intelligencebusinessScale modelcomputer030217 neurology & neurosurgeryScientific Reports
researchProduct

Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces

2020

Abstract Background Intra-tumour heterogeneity in lymphoid malignancies encompasses selection of genetic events and epigenetic regulation of transcriptional programs. Clonal-related neoplastic cell populations are unsteadily subjected to immune editing and metabolic adaptations within different tissue microenvironments. How tissue-specific mesenchymal cells impact on the diversification of aggressive lymphoma clones is still unknown. Methods Combining in situ quantitative immunophenotypical analyses and RNA sequencing we investigated the intra-tumour heterogeneity and the specific mesenchymal modifications that are associated with A20 diffuse large B-cell lymphoma (DLBCL) cells seeding of d…

0301 basic medicinediffuse large B-cell lymphoma; digital spatial profiling; intra-tumour heterogeneity; microenvironment; SPARClcsh:MedicineMice0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesTumor MicroenvironmentIn Situ Hybridizationlcsh:R5-920Matricellular proteinGeneral MedicineDiffuse large B-cell lymphomaPrognosisGene Expression Regulation NeoplasticPhenotype030220 oncology & carcinogenesisLymphoma Large B-Cell Diffuselcsh:Medicine (General)Research PaperStromal cellMicroenvironmentTumour heterogeneityBiologySettore MED/08 - Anatomia PatologicaModels BiologicalGeneral Biochemistry Genetics and Molecular BiologyImmunophenotypingGenetic Heterogeneity03 medical and health sciencesImmune systemCell Line TumorBiomarkers TumormedicineAnimalsHumansEpigeneticsSequence Analysis RNAGene Expression Profilinglcsh:RMesenchymal stem cellComputational BiologySPARCDigital spatial profilingmedicine.diseaseIntra-tumour heterogeneityDisease Models Animal030104 developmental biologyCancer researchNeoplastic cellStromal CellsTranscriptomeDiffuse large B-cell lymphoma
researchProduct

Histidine tracts in human transcription factors: insight into metal ion coordination ability

2017

Consecutive histidine repeats are chosen both by nature and by molecular biologists due to their high affinity towards metal ions. Screening of the human genome showed that transcription factors are extremely rich in His tracts. In this work, we examine two of such His-rich regions from forkhead box and MAFA proteins—MB3 (contains 18 His) and MB6 (with 21 His residues), focusing on the affinity and binding modes of Cu2+ and Zn2+ towards the two His-rich regions. In the case of Zn2+ species, the availability of imidazole nitrogen donors enhances metal complex stability. Interestingly, an opposite tendency is observed for Cu2+ complexes at above physiological pH, in which amide nitrogens part…

0301 basic medicineinorganic chemicalsMaf Transcription Factors LargeStereochemistryMetal ions in aqueous solutionPeptideNerve Tissue Proteins010402 general chemistry01 natural sciencesBiochemistryInorganic ChemistryMetal03 medical and health scienceschemistry.chemical_compoundCoordination ComplexesAmideImidazoleHomeostasisHumansHistidineAmino Acid SequenceTranscription factorHistidineLigand bindingchemistry.chemical_classificationOriginal PaperMass spectrometryForkhead Transcription FactorsHydrogen-Ion ConcentrationPeptide Fragments0104 chemical sciencesZinc030104 developmental biologyBinding affinitychemistryvisual_artPeptidevisual_art.visual_art_mediumThermodynamicsHuman genomeCopperProtein BindingJournal of Biological Inorganic Chemistry
researchProduct

IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis

2018

Interleukin (IL)-25, a member of the IL-17 cytokine superfamily, is produced by immune and non-immune cells and exerts type 2 pro-inflammatory effects in vitro and in vivo. The IL-25 receptor(R) is composed of the IL-17RA/IL-17RB subunits. Previous work showed that germinal centre (GC)-derived B-cell non Hodgkin lymphomas (B-NHL) expressed IL-17AR, formed by IL-17RA and IL-17RC subunits, and IL-17A/IL-17AR axis promoted B-NHL growth by stimulating neoangiogenesis. Here, we have investigated expression and function of IL-25/IL-25R axis in lymph nodes from human GC-derived B-NHL, i.e. Follicular Lymphoma (FL,10 cases), Diffuse Large B Cell Lymphoma (6 cases) and Burkitt Lymphoma (3 cases). Tu…

0301 basic medicinelcsh:Immunologic diseases. AllergyPathologymedicine.medical_specialtyAngiogenesismedicine.medical_treatmentImmunologyFollicular lymphomalcsh:RC254-282Angiogenesis; B lymphocytes; B-NHL; Cytokines; IL-25; Tumor immunology; Immunology and Allergy; Immunology; Oncology03 medical and health sciencesangiogenesisIL-25immune system diseaseshemic and lymphatic diseasesmedicineImmunology and AllergyCytokineOriginal ResearchB lymphocyteChemistryGerminal centerInterleukinmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenscytokinesLymphomaAngiogenesi030104 developmental biologyCytokineOncologyCancer researchB-Cell Non-Hodgkin LymphomaTumor immunologyB-NHLb lymphocyteslcsh:RC581-607Diffuse large B-cell lymphoma
researchProduct

A rare rarity: neuroendocrine tumor of the esophagus

2019

Abstract Esophageal Neuroendocrine tumors (NETs) are rare, aggressive and lacking specific symptoms. This causes a diagnostic delay, worsening the prognosis. Numerous cases are reported in literature, without a consensus on the management. Our aim was to clarify epidemiology, clinical presentation, diagnostic, therapeutic management of esophageal NETs. Extensive literature search identified a total of 226 articles. One hundred twenty-five articles (n = 1676) met the inclusion criteria, showing that: the incidence of esophageal NET varies geographically; men (60–70 years) are more affected; smoking and alcohol abuse are the major risk factors; dysphagia, weight loss, appetite loss are the mo…

0301 basic medicinemedicine.medical_specialtyCarcinoid tumorsesophageal neoplasmsNeuroendocrine tumorsSmall-cell carcinomaGastroenterology03 medical and health sciences0302 clinical medicinegastroenteropancreatic NETInternal medicineEpidemiologymedicinerisk factorsesophageal NEC; gastroenteropancreatic NET; large cell esophageal NEN; MANEC; small cell carcinoma; delayed diagnosis; esophageal neoplasms; humans; neuroendocrine tumors; prognosis; rare diseases; risk factorsEsophagusStage (cooking)esophageal NECdelayed diagnosishumanssmall cell carcinomabusiness.industryLarge cellMANECrare diseasesHematologymedicine.diseaseDysphagia030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesislarge cell esophageal NENprognosismedicine.symptomneuroendocrine tumorsbusiness
researchProduct

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymp…

2016

Abstract Purpose. To evaluate the safety, tolerability and efficacy of the combination of the mTOR inhibitor Temsirolimus and a standard salvage regimen (R-DHAP) in patients with relapsed or refractory diffuse large cell B-Cell lymphoma (DLBCL). Methods. This is a prospective, multicenter, phase II, open-label study. Patients with relapsed or refractory DLBCL with a maximum of two prior treatment lines were eligible. The STORM regimen consisted of Rituximab 375 mg/m² (day 2) and DHAP (Dexamethasone 40mg day 3-6, Cisplatine 100 mg/m² day 3, Cytarabine 2x2 g/m² day 4) with Temsirolimus added on day 1 and 8 of a 21 d cycle, with 2-4 cycles planned. In part I, dose levels of 25, 50, 75 and 100 …

0301 basic medicinemedicine.medical_specialtyImmunologyNeutropeniaBiochemistry03 medical and health sciences0302 clinical medicineMedian follow-upInternal medicinemedicineLeukopeniabusiness.industryCell BiologyHematologymedicine.diseaseTemsirolimusSurgeryRegimen030104 developmental biologyTolerability030220 oncology & carcinogenesisRituximabmedicine.symptombusinessDiffuse large B-cell lymphomamedicine.drugBlood
researchProduct

Early diagnosis of intravascular large B-cell lymphoma.

2016

030207 dermatology & venereal diseases03 medical and health sciencesIntravascular large B-cell lymphomaPathologymedicine.medical_specialty0302 clinical medicinebusiness.industry030220 oncology & carcinogenesismedicineDermatologymedicine.diseasebusinessJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct